Bolt Biotherapeutics
900 Chesapeake Drive
Redwood City
CA
94063
United States
Tel: (650) 665-9295
Website: https://www.boltbio.com/
Email: careers@boltbio.com
About Bolt Biotherapeutics
Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.
Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.
90 articles about Bolt Biotherapeutics
-
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
4/10/2021
Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study
-
Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
4/8/2021
Bolt Biotherapeutics announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 AM ET.
-
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
3/31/2021
Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising
-
Money on the Move: February 3-9
2/10/2021
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients. -
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2/9/2021
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock, inclusive of the full exercise by the underwriters of their option to purchase 1,725,000 shares of common stock, at a price to the public of $20.00 per share.
-
Innate immune-oncology company Bolt expects to raise $230 million, and cancer cell therapy player Vor Biopharma expects to raise $176.9 million, in upsized initial public offerings (IPOs) starting today, following yesterday’s $587.5 million IPO for Sana Biotechnology and other financing news this...
-
Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen LaPorte
1/5/2021
Bolt Biotherapeutics Inc., a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today announced the appointment of Kathleen LaPorte, to its Board of Directors
-
Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting
12/9/2020
Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today announced the presentation of a poster detailing the design of its ongoing Phase 1/2 clinical trial for BDC-1001 in patients with HER2-expressing solid tum
-
Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics' Boltbody™ ISAC Platform
12/7/2020
Peer-reviewed publication demonstrates that Boltbody ISAC treatment leads to complete clearance of large HER2-expressing tumors and protective immunological memory in preclinical models
-
Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
11/10/2020
Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today presented the trial design of its ongoing Phase 1/2 clinical trial and preclinical data demonstrating proof-of-concept of its lead clinical drug candidate, BDC-1001.
-
Bolt Biotherapeutics Closes $93.5 Million Series C Financing
7/1/2020
Proceeds to support continued clinical advancement of BDC-1001 in HER2-expressing cancers and acceleration of pipeline expansion with ISAC Boltbody™ platform technology [01-July-2020] REDWOOD CITY, Calif. , July 1, 2020 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platfor
-
Clinical-stage biotechnology company Bolt Biotherapeutics announced today that it has completed a $93.5 million Series C round of financing, led by Sofinnova Investments.
-
Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001
6/9/2020
Patent issuance protects the Boltbody™ ISAC technology platform as a potentially disruptive solution to the challenges facing current oncology therapeutics [09-June-2020] REDWOOD CITY, Calif. , June 9, 2020 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform tec
-
Bolt Biotherapeutics to Present at 2020 Jefferies Virtual Healthcare Conference
5/27/2020
Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that Randall Schatzmann , Ph.D., chief executive officer of Bolt, will present a company overview at
-
BioSpace Movers & Shakers, May 15
5/15/2020
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers. -
Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial Officer
5/12/2020
Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing Immune-Stimulating Antibody Conjugates (ISACs) to harness the power of the immune system to treat cancer, today announced the appointment of William P. Quinn as chief financial officer.
-
BioSpace Movers & Shakers, April 10
4/10/2020
Biopharma companies strengthen their leadership teams and boards with this week's Movers & Shakers. -
Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer
4/9/2020
Bolt Biotherapeutics, Inc.,today announced the appointment of Edith Perez, M.D., as chief medical officer.
-
Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality
4/2/2020
- Dr. Ihle's extensive background in chemistry, manufacturing and controls of antibody drug conjugate therapeutics will support the advancement of Bolt's clinical program (BDC-1001) and its pipeline -
-
Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
3/26/2020
Bolt Biotherapeutics, Inc., a private biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that patient dosing has begun